Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.

At the same time, American depository receipts of rival Novo Nordisk plunged nearly 8% yesterday, as investors view Lilly to be even more competitive with the new orforglipron data. (Lilly is up ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

The Justice Department under President Donald Trump is reconsidering the legal basis for Peter Navarro’s 2023 conviction for criminal contempt of Congress, according to court filings reviewed by ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Defense Secretary Pete Hegseth may have shared details of a sensitive attack against Yemen in a second Signal app group chat with his family last month, according to a report published by The New ...

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races! This morning, the Indianapolis-based pharmaceutical giant announced that its new GLP-1 weight loss pill ...